TORONTO, Sept. 27, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), todayannounced that Dr. Eric Brouwer, Ph.D, has joined SQI as the Chief Scientific Officer ("CSO"). In this capacity, he will be responsible for developing and executing the Company's Research and Development programs.
SQI is a Toronto-based life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics.
Dr. Brouwer is an accomplished leader in the life sciences sector, with experience in assay design and development, product launch, clinical studies and regulatory submissions. He was most recently the Chief Scientific Officer of Trinity Biotech, of Bray, Ireland, and CEO of Trinity Biotech's Swedish subsidiary, Fiomi Diagnostics AB. Trinity Biotech develops, manufactures and markets diagnostics products in autoimmune disease, cardiac markers, infectious disease, and point of care tests.
Before working at Trinity, Dr. Brouwer was employed at Abbott Laboratories for 15 years and held progressively senior positions leading Assay Research and Development in Point of Care diagnostics lastly serving as Director, Assay Research and Development.
Dr. Brouwer received his Ph.D. in Chemistry from Carleton University in Ottawa and served there as Adjunct Chemistry Professor from 2000 to 2005.
"SQI presents an exciting opportunity for me to bring my years of experience in assay development to an innovator in the life sciences market," said Dr. Eric Brouwer. "I am looking forward to joining the team that delivers SQI's commercial and technological goals."
"We are very pleased to have Dr. Brouwer join us at this very exciting time in our corporate development," said Andrew Morris, CEO of SQI Diagnostics. "Eric brings a combination of product launching, scientific and leadership skills that will help propel SQI to the next level."
About SQI DiagnosticsSQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.
Sales and Marketing Contact:
Vice President, Global Commercial OperationsRuss Peloquin913.email@example.com
Investor Relations Contacts:
Chief Executive Officer Andrew Morris 416.674.9500 ext. 229 firstname.lastname@example.org
Vice President, Finance and Administration Patricia Lie 416.674.9500 ext. 277 email@example.com
Forward-looking Statements This press release contains certain statements including, without limitation, the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "believe", "in the process", "benefits", "leading to", "position" "possible", "is subject to" and other similar expressions which may constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic consumable kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future.
Such statements, risks and uncertainties are detailed in the Company's ongoing filings with the securities regulatory authorities, and are available to the public at www.sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...